No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BCRX BioCryst Pharmaceuticals
- 4.210
- -0.170-3.88%
Close Apr 24 16:00 ET
- 4.190
- -0.020-0.48%
Post 19:31 ET
867.89MMarket Cap-3567P/E (TTM)
4.420High4.180Low4.41MVolume4.370Open4.380Pre Close18.77MTurnover2.31%Turnover RatioLossP/E (Static)206.15MShares9.06552wk High-1.90P/B803.61MFloat Cap4.18052wk Low--Dividend TTM190.88MShs Float37.250Historical High--Div YieldTTM5.48%Amplitude0.600Historical Low4.257Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
With 80% Ownership, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Boasts of Strong Institutional Backing
BioCryst to Report First Quarter 2024 Financial Results on May 6
RESEARCH TRIANGLE PARK, N.C., April 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2024 financial results on Monday, May 6,
FYBR, BCRX and SABR Are Among After Hour Movers
Express News | BioCryst Pharmaceuticals Announced That The Brazilian Health Regulatory Agency Has Granted Approval For Oral, Once-daily ORLADEYO (Berotralstat) For The Prophylaxis Of Hereditary Angioedema (Hae) Attacks In Adults And Pediatric Patients 12 Years
Express News | BioCryst Announces Approval of Orladeyo® (Berotralstat) by the Brazilian Health Regulatory Agency
Express News | Needham Reiterates Buy on BioCryst Pharma, Maintains $12 Price Target
Comments
$BioCryst Pharmaceuticals(BCRX.US$
NEWS
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency
NEWS
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency
1
Don’t put much into analyst’s targets, but!
$BioCryst Pharmaceuticals(BCRX.US$ Still with the buy rating with a 12 PT!
1
American Biotech Company Presents Data That Treats Hereditary Angioedema
Unprecedented HAE Attack Rate Reductions with ORLADEYO® (berotralstat): A Breakthrough in Medical Science.
BioCryst Pharmaceuticals, Inc., a leading American biotechnology company, has presented new real-world data that shows significant and sustained reductions in hereditary angioedema (HAE) attack rates after patients began treatment with ORLADEYO® (berotralstat). This groundbreaking development could have far-reaching imp...
BioCryst Pharmaceuticals, Inc., a leading American biotechnology company, has presented new real-world data that shows significant and sustained reductions in hereditary angioedema (HAE) attack rates after patients began treatment with ORLADEYO® (berotralstat). This groundbreaking development could have far-reaching imp...
1
Update
$BioCryst Pharmaceuticals(BCRX.US$ BioCryst Pharmaceuticals Says New Analyses Of Real-world Use Of Oral, Once-daily Orladeyo (Berotralstat) Showed Patients Who Initiated Orladeyo Experienced Rapid, Substantial And Sustained Reductions In Attack Rates Through 18 Months Of Treatment
1
2
News
$BioCryst Pharmaceuticals(BCRX.US$ RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Italian Medicines Agency, Agenzia Italiana del Farmaco (AIFA), has finalized reimbursement and recommended ORLADEYO® (berotralstat) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in eligible patients 12 years and older. With this recommendation, HAE patients in Italy now have access to the fi...
7
6
生日快乐Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg